Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Temozolomide is an effective alkylating agent that is increasingly used for the treatment of pediatric brain tumors. Secondary, or treatment-related, myelodysplasia is a life-threatening complication of alkylating chemotherapy and has been reported in children with brain tumors after treatments other than temozolomide. We describe for the first time a case of temozolomide-related myelodysplasia in a child.
Dufour
Christelle
C
Département de Cancérologie de l'Enfant et de l'Adolescent, Institut Gustave Roussy, 39, rue Camille Desmoulins, Villejuif cedex 94805, France. dufour@igr.fr
Da Costa
Lydie
L
Auger
Nathalie
N
Jullien
Marc
M
Bhangoo
Ranjeev
R
Grill
Jacques
J
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide